Five-year data from the Phase III POLARIX study (abstract #469) reinforce the potential of Polivy in combination with Rituxan ® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) to ...
Genentech, a member of the Roche (RHHBY), announced that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology, or ASH, annual meeting and ...
Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma #782 oral presentation ...
--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of the positive Phase III INAVO120 results, evaluating Itovebi TM ...
Independent Online, popularly known as IOL, is one of South Africa’s leading news and information websites bringing millions of readers breaking news and updates on Politics, Current Affairs ...
UCB will advance its anti-tau antibody for Alzheimer’s disease solo after Roche and Genentech walked away from the asset known as bepranemab.
UCB granted Roche and its biotech unit Genentech an exclusive worldwide license to bepranemab, then called UCB0107, in 2020 as part of a deal worth around $2 billion in milestones. The agreement ...
--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from the open-label, single-arm Phase IV ELEVATUM study ...
https://www.tipranks.com/news/the-fly/stryker-price-target-raised-to-400-from-360-at-canaccord Genentech, a member of the Roche (RHHBY), announced topline one-year ...
– The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with DME treated with Vabysmo who identify as African American, Black, Hispanic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback